RIHAWI, KARIM
 Distribuzione geografica
Continente #
NA - Nord America 651
EU - Europa 568
AS - Asia 281
AF - Africa 53
Totale 1.553
Nazione #
US - Stati Uniti d'America 649
IT - Italia 241
CN - Cina 106
GB - Regno Unito 76
VN - Vietnam 69
DE - Germania 64
SE - Svezia 64
SG - Singapore 60
IE - Irlanda 38
IN - India 28
TG - Togo 27
BG - Bulgaria 18
CH - Svizzera 15
FR - Francia 15
CI - Costa d'Avorio 11
JO - Giordania 10
EE - Estonia 7
UA - Ucraina 7
ZA - Sudafrica 7
FI - Finlandia 6
NG - Nigeria 6
RU - Federazione Russa 6
BE - Belgio 5
HK - Hong Kong 5
AT - Austria 2
CD - Congo 2
NL - Olanda 2
TW - Taiwan 2
CA - Canada 1
CZ - Repubblica Ceca 1
GR - Grecia 1
PA - Panama 1
UZ - Uzbekistan 1
Totale 1.553
Città #
Chandler 85
Fairfield 68
Southend 67
Bologna 65
Singapore 58
Ashburn 56
Houston 45
Woodbridge 44
Dublin 38
Seattle 37
Dong Ket 34
Wilmington 29
Princeton 28
Lomé 27
Cambridge 23
Florence 19
Sofia 18
Vicenza 18
Beijing 17
Bern 15
Turin 13
Santa Clara 12
Abidjan 11
Amman 10
Redmond 9
Shanghai 9
Berlin 8
Bremen 8
Jinan 8
Milan 8
New York 8
Westminster 8
Ann Arbor 7
Forlì 7
Nanjing 7
Abeokuta 6
Los Angeles 6
Tianjin 6
Brussels 5
Hebei 5
Helsinki 5
San Diego 5
Boydton 4
Falls Church 4
Rome 4
Shenyang 4
Boardman 3
Bühl 3
Carpi 3
Changsha 3
Hangzhou 3
Medford 3
Naples 3
Padova 3
Paris 3
Redwood City 3
Arzano 2
Cesena 2
Dearborn 2
Des Moines 2
Formigine 2
Fuzhou 2
Groningen 2
Hong Kong 2
Imola 2
Ithaca 2
Kilburn 2
Kinshasa 2
Messina 2
Modena 2
Montelupone 2
Mülheim 2
Palermo 2
Pescara 2
Prescot 2
Pune 2
Rimini 2
Taipei 2
Vienna 2
Xiamen 2
Bassano Del Grappa 1
Bedford 1
Casalecchio di Reno 1
Castel San Pietro Terme 1
Castenaso 1
Castiglione dei Pepoli 1
Changzhou 1
Chengdu 1
Clearwater 1
Cogollo del Cengio 1
Costa Mesa 1
Ferrara 1
Foshan 1
Guangzhou 1
Jiaxing 1
Kato Synoikia Trikalon 1
Kunming 1
Lana 1
Lanzhou 1
Lappeenranta 1
Totale 1.076
Nome #
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 142
A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. 133
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 128
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence 118
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins 117
Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies 116
Chemotherapy treatment in malignant pleural mesothelioma: A difficult history 110
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 110
BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience 92
Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer 83
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study 73
Expected and non-expected immune-related adverse events detectable by CT 66
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer 61
Emerging therapies in malignant pleural mesothelioma 60
Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: A case series 53
Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: Novel translational implications 50
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? 47
IL-1 Associated Post Senescence Reprogramming Impairs Response To EGFR Neutralization 41
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer 17
Immune checkpoint inhibition in small cell lung cancer: A key to reach an unmet need? 9
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 2
Totale 1.628
Categoria #
all - tutte 5.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.127


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020222 0 0 0 22 27 21 33 34 40 13 17 15
2020/2021241 23 25 25 0 26 6 12 8 13 9 15 79
2021/2022221 7 2 7 4 17 16 5 27 16 19 60 41
2022/2023537 21 54 12 56 49 68 30 35 88 13 66 45
2023/2024182 16 22 15 15 19 40 5 6 10 21 6 7
2024/2025148 12 78 51 7 0 0 0 0 0 0 0 0
Totale 1.628